https://scholars.lib.ntu.edu.tw/handle/123456789/415322
標題: | Antidepressant Prescription and Risk of Lung Cancer: A Nationwide Case-Control Study | 作者: | HSIAO-YU YANG Pau-Chung CHEN Chen C.-J. PAU-CHUNG CHEN McIntyre R.S. Chen V.C.-H. |
關鍵字: | antidepressants; catastrophic illness; defined daily dose; lung cancer; national health insurance database | 公開日期: | 2019 | 出版社: | Georg Thieme Verlag | 卷: | 52 | 期: | 3 | 起(迄)頁: | 134-141 | 來源出版物: | Pharmacopsychiatry | 摘要: | Introduction In recent decades, concern about safety of antidepressants has been raised but the risk between antidepressants and lung cancer has not yet been established. Methods A case-control study was conducted by using a nationwide database in Taiwan. The case groups were new onset lung cancer diagnosis during 1999-2008 and age- and gender-matched controls were selected among those without any cancer. The cumulative exposure dose before the lung cancer diagnosis was added and risks were calculated according to the levels of defined daily dose and classes of antidepressants. Results A total of 39,001 individuals with lung cancer and 189,906 individuals without lung cancer between 1999 and 2008 were included in the analysis. Antidepressants, of any class, were not associated with elevated risks for lung cancer with the exception of bupropion at high exposure levels (odds ratio=4.81, 95% confidence interval=1.39-16.71). Discussion Antidepressant prescription was not associated with elevation of lung cancer incidence using a nationally representative sample. The elevated risk for lung cancer with bupropion at high doses may be a bias by indication and warrant longitudinal investigation. ? 2019 Georg Thieme. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045677570&doi=10.1055%2fa-0596-0819&partnerID=40&md5=11e5b98d9c6bb8d6f4c6cb2713e36556 https://scholars.lib.ntu.edu.tw/handle/123456789/415322 |
ISSN: | 1763679 | DOI: | 10.1055/a-0596-0819 | SDG/關鍵字: | amfebutamone; amitriptyline; antidepressant agent; citalopram; clomipramine; dosulepin; doxepin; duloxetine; escitalopram; fluoxetine; fluvoxamine; imipramine; maprotiline; melitracen; milnacipran; mirtazapine; monoamine oxidase inhibitor; paroxetine; serotonin noradrenalin reuptake inhibitor; serotonin uptake inhibitor; sertraline; trazodone; tricyclic antidepressant agent; venlafaxine; amfebutamone; antidepressant agent; adult; age; aged; Article; cancer incidence; cancer risk; case control study; controlled study; depression; drug exposure; female; gender; human; lung cancer; major clinical study; male; middle aged; odds ratio; prescription; priority journal; risk assessment; systematic error; Taiwan; very elderly; chemically induced; longitudinal study; lung tumor; public health; retrospective study; risk factor; statistics and numerical data; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Female; Humans; Longitudinal Studies; Lung Neoplasms; Male; National Health Programs; Prescriptions; Retrospective Studies; Risk Factors; Taiwan |
顯示於: | 環境與職業健康科學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。